August 2024 – Page 254 – Get News Story

Pioneer Recovery Center Outlines Key Factors to Consider When Seeking Addiction Treatment

Pioneer Recovery Center is a leading drug rehab facility. In a recent update, the facility outlined key factors to consider when seeking addiction treatment.

Hibbing, MN – In a website post, Pioneer Recovery Center outlined key factors to consider when seeking addiction treatment.

The professionals noted that one important factor is the type of addiction treatment Hibbing offered. Different treatment centers provide various programs, such as inpatient, outpatient, and intensive outpatient programs. For example, inpatient programs often provide the most intensive care, offering a structured environment with 24/7 support. It is vital to evaluate the level of care required based on the severity of the addiction and personal circumstances.

The team mentioned that another crucial factor is the availability of addiction treatment counseling Hibbing. Effective counseling can address underlying issues contributing to addiction. Treatment centers that offer a variety of counseling options, including individual therapy, group therapy, and family therapy, can provide comprehensive support. The right counseling approach can help individuals develop coping mechanisms, enhance communication skills, and develop a strong support network.

The team said that it is essential to consider the general setting and amenities of the addiction treatment center Hibbing. A comfortable, welcoming setting can significantly impact the recovery experience. Facilities that offer holistic therapies, such as yoga, meditation, and art therapy, can enhance the treatment process by promoting relaxation and self-expression. Additionally, centers that provide recreational activities, fitness programs, and nutritious meals contribute to overall well-being and a positive outlook on recovery.

About Pioneer Recovery Center

Pioneer Recovery Center is a top-rated drug rehab facility. It functions as an essential outreach center committed to assisting people in their journey toward addiction recovery. The office is crucial in connecting the local community with comprehensive addiction treatment resources and services available at the main headquarters in Cloquet, MN. The crew is committed to providing essential support and guidance to those seeking information and assistance with addiction treatment options.

Media Contact
Company Name: Pioneer Recovery Center
Contact Person: Jennifer Silverness
Email: Send Email
Phone: (218) 683-1782
Address:2125 2nd Ave E
City: Hibbing
State: MN
Country: United States
Website: https://www.pioneerrecoverycenter.com/addiction-treatment-center-hibbing

Navigating To New Heights: LiTime Partners With ABYC To Elevate Boating Safety And Innovation

LiTime, a leader in LiFePO4 batteries, announces its lithium marine batteries meet ABYC E-13 standards. With LiTime product department staff certified as ABYC technicians, this ensures superior safety, quality, and technical reliability for LiTime lithium marine batteries.

What is ABYC? What Does Compliance Mean for Consumers?

What is ABYC? The American Boat and Yacht Council (ABYC) is a non-profit organization dedicated to developing and promoting safety standards for boat design, construction, maintenance, and operation. Its primary goal is to enhance the reliability and performance of boats. The standards are referenced by the U.S. Navy and the U.S. Coast Guard. A USCG/ABYC Risk Mitigation Webinar report on May 2, 2024, revealed that boats certified to ABYC standards are 43% to 47% less likely to be involved in certain types of accidents, demonstrating the effectiveness of ABYC standards in preventing potential hazards that lead to boat accidents.

What is ABYC E-13? The ABYC E-13 standard, effective August 1, 2023, is one of the many standards developed by the American Boat and Yacht Council. It specifically addresses the manufacturing, selection, and installation of lithium marine batteries. This standard includes requirements for Battery Management Systems (BMS), installation locations and methods, waterproof and fire protection measures, overcurrent protection, and thermal runaway prevention, ensuring the safety of lithium batteries in marine applications.

What Does This Mean for Consumers? LiTime’s marine LiFePO4 batteries meeting the ABYC E-13 standard signifies superior manufacturing capabilities and enhanced user safety. By using LiTime outboard motor batteries, trolling motor batteries, and cranking batteries certified to ABYC E-13, users benefit from professional safety guarantees and potential insurance cost reductions due to adherence to recognized standards.

ABYC E-13 Lithium Battery Standard and LiTime LiFePO4 Batteries

In six key aspects, the ABYC E-13 lithium battery standard is relevant to users:

1. All battery systems are recommended to have a BMS.

2. The BMS should protect against overcharge, over-discharge, overheating, overcurrent, and short circuits.

3. The battery ought to pass at least one standard test such as UL, IEC, or SAE.

4. The battery and its system components should be waterproof.

5. The battery should be quickly and safely accessible and operable in emergencies without tools.

6. Lithium battery systems should be installed, commissioned, and maintained according to the manufacturer’s recommendations.

Features of LiTime Lithium Marine Batteries:

1. They are equipped with a BMS protection system, offering five basic protections: overcharge, over-discharge, overheating, overcurrent, and short circuit.

2. The LiTime BMS provides 20 layers of battery protection, including but not limited to 500A/1S discharge, automatic recovery after overload protection (30 seconds), pre-charge function, moisture resistance, and salt spray protection (specific to the battery model).

3. LiTime batteries have passed multiple standard tests including UL1973, FCC, CE, RoHS, and UN38.3 (specific to the battery model).

4. LiTime marine batteries are certified for IP65 or IP67 waterproofing and splash-proofing.

5. LiTime Bluetooth series batteries feature wireless Bluetooth operation, supporting battery shutdown and power status checks via mobile phone.

6. LiTime provides professional technical support and online services to guide users in correct battery installation.

The comparison above shows that LiTime marine LiFePO4 batteries closely align with the key elements of the ABYC E-13 standard. This ensures user safety from a design perspective, preventing battery fires and other accidents, while also providing installation guidelines to reduce user liability in potential accidents.

Focusing on user needs, LiTime continues to innovate, launching two new marine battery models this year, specifically designed for electric outboard motors and trolling motors, both meeting ABYC E-13 standards.

With LiTime Bluetooth 5.0 technology, users can control power status via mobile apps, upgrading batteries to smart systems. Utilizing LiTime’s unique BMS technology and IP65 waterproof and dustproof design, the batteries include low-temperature charging cutoff functions, offering 20+ layers of battery protection and quality certifications such as UL1973, FCC, CE, RoHS, and UN38.3, fundamentally reducing risks of fire, leakage, and charging under low temperatures. Both batteries are Group 31 size, fitting the original battery trays on boats for easy replacement of old lead-acid batteries.

LiTime 12V 100Ah Electric Outboard Motor Lithium Marine Battery: A professional battery for marine electric outboard motors, compatible with power and horsepower ranges from 1280W and 3.5HP in a 1S1P setup to 6400W and 14.5HP in a 5S1P setup. It supports configurations up to 5S5P for a total of 60V 500Ah, accommodating the needs of outdoor enthusiasts using 24V, 36V, 48V, and 60V electric outboard motors.

LiTime 12V 100Ah TM Lithium Marine Trolling Motor Battery with Bluetooth: A professional marine trolling motor battery, supporting up to 4S4P configurations to 51.2V 400Ah, suitable for 30-70 lbs trolling motors and 12V DC loads on boats.

About LiTime

Headquartered in Shenzhen, China, LiTime is celebrating its 15th year in the new energy storage field this August. Over the past 15 years, LiTime has consistently prioritized user needs, continuously advancing battery innovation technology to provide LiFePO4 storage batteries that cover all scenarios. In the marine application field, LiTime has obtained certifications from the American Boat and Yacht Council and the American Sportfishing Association. LiTime is committed to contributing to the reduction of the global carbon footprint and transforming the power grid landscape.

Media Contact
Company Name: Shenzhen LiTime Technology Co., Ltd
Contact Person: Shafee Chang
Email: Send Email
City: Shenzhen
Country: China
Website: https://www.litime.com/

Six Brothers Contractors Reveals Surprising Trends in Commercial Roof Replacement Costs Across New Jersey

six brothers contractors commercial roofing NJ experts

Six Brothers Contractors Reveals Surprising Trends in Commercial Roof Replacement Costs Across New Jersey

In a groundbreaking analysis of commercial roofing trends, Six Brothers Contractors, a leading roofing company based in Lincoln Park, New Jersey, has uncovered surprising insights into the cost to replace a commercial roof in New Jersey. This comprehensive study sheds light on factors influencing pricing and offers valuable guidance for business owners facing roofing decisions.

Richard Ala, founder of Six Brothers Contractors, stated, “Our research reveals that the average cost to replace a commercial roof in New Jersey has increased by 15% over the past two years, outpacing general inflation. However, we’ve also identified strategies that can significantly reduce these costs without compromising quality.”

Key findings from the study include:

1. Material Matters: The choice of roofing material dramatically impacts the cost to replace a commercial roof in New Jersey. While traditional materials like EPDM rubber remain popular, newer options such as TPO (Thermoplastic Polyolefin) are gaining traction due to their energy efficiency and cost-effectiveness.

2. Size and Complexity: Unsurprisingly, roof size is a primary factor in replacement costs. However, the study found that roof complexity – including the number of penetrations, equipment mounts, and overall shape – can increase costs by up to 25%.

3. Regional Variations: The cost to replace a commercial roof in New Jersey varies significantly by region. Urban areas like Newark and Jersey City tend to have higher costs due to increased labor and logistics expenses, while more rural areas offer more competitive pricing.

4. Energy Efficiency Pays Off: Investments in energy-efficient roofing materials, while initially more expensive, can reduce long-term costs. The study found that businesses investing in high-efficiency roofing systems recouped their additional costs within 5-7 years through energy savings.

5. Timing is Everything: The research revealed that scheduling roof replacements during the off-peak season (late fall to early spring) can result in savings of up to 10% on the total cost to replace a commercial roof in New Jersey.

Dr. Emily Rothstein, a commercial real estate analyst not affiliated with the study, commented, “This research provides invaluable insights for property owners and managers across New Jersey. Understanding these cost factors can lead to more informed decision-making and potentially significant savings.”

Six Brothers Contractors’ analysis also highlighted the importance of regular maintenance in extending roof life and reducing long-term replacement costs. The company found that well-maintained roofs lasted 25-30% longer than those receiving minimal upkeep, substantially decreasing the lifetime cost of commercial roofing.

“While the initial cost to replace a commercial roof in New Jersey can be substantial, our study shows that informed choices and proactive maintenance can lead to considerable savings over time,” Ala added. “We’re committed to helping businesses make smart roofing decisions that protect their investments and improve their bottom line.”

The full report, titled “Navigating the Complexities of Commercial Roof Replacement Costs in New Jersey,” is available upon request and offers detailed insights into pricing trends, material comparisons, and cost-saving strategies.

About Six Brothers Contractors:

Founded by Richard Ala, Six Brothers Contractors is a premier roofing company serving businesses across New Jersey. With a commitment to quality, innovation, and customer satisfaction, Six Brothers Contractors has established itself as a trusted name in commercial roofing solutions.

Media Contact
Company Name: Six Brothers Contractors
Contact Person: Richard Ala
Email: Send Email
Phone: (201) 650-3321
Address:41 Algonquin Ave, Lincoln Park
City: Morris County
State: New Jersey 07035
Country: United States
Website: www.sixbrotherscontractors.com/

In the Midst of Danger: Sitong Cao Solo Exhibition

Time：July 29 – August 3, 2024

Location: The Blanc Gallery,

Famous 20th-century poet Rainer Maria Rilke once discussed the relationship between the barrenness of his own soul and artistic creation in a letter to his wife. He candidly admitted that a work of art is the result of being “in danger.” This fundamental stimulus, The Central Goad, resides long within the artist, conveying purpose and emotion, briefly and fleetingly attacking the latter’s soul. Therefore, Rilke referred to himself as an invisible bee, crazily plundering the tangible honey and storing it in a vast golden hive.

Exhibition View, 2024

Visual artist Si Tong currently resides in New York City. In her works, she has consistently adhered to the concept of creating in a state of “being in danger,” attempting to find a territory for her emotional spectrum in the midst of chaotic and noisy life. In the majority of her works, she combines cross-space theory with psychoanalytic methodology, focusing on the refinement of things that are often difficult to notice yet omnipresent in daily life – foggy grasslands, snakes, cigarettes… Most of them are presented from symmetrical and orderly angles and compositions. Imagine how to extract the audience and emotions from a segment of imagery.

American scholar Yi-fu Tuan once explored the difference between space and place in his book. Geographical space, in its physical sense, becomes a place due to the traces of people’s daily production and life, as well as the emotional dependencies hidden and emanating through their movements. In spatial studies, individual and collective psyches under the spatial perspective hold significant importance. Through the medium of photography, artist Si Tong explores the infinite subtle differences that stretch across place and space, deconstructing the traditional meanings of space. When viewing her works, various emotions unfold slowly like a rolled scroll before the viewer. The artist achieves a presence of “being there” in the field, integrating her emotions and philosophy into the narrative system as part of the image frame.

Exhibition View, 2024

“They stem from my own experiences with depression, telling the complexity of our traumas, narrowing the scope of connection and gaze between the self and the ‘other’…” During an interview, Si Tong expressed her creative purpose for her artworks. A remarkable artist is often also a naturalist. They not only need to understand the relationships between images but also have a clear perception and identification of all creations on Earth, everything that currently exists. If all creations are likened to existing nouns, then the artist’s mission is to retell these nouns with individual sensory experiences. Therefore, there exists a linear compassion between the two, which is akin to the intertextual connection that Si Tong maintains with her work.

In “Thus They Spoke,” the artist explores and recalls various violence she has experienced in the past, transforming them into a stream of consciousness through fragmented memories in imagery – walking barefoot on grass, a snake weaving through fingers… Using natural imagery as metaphors for intimate relationships and traumatic memories, the artist employs improvisational and non-stage performance methods to explore the traces of personal memory connection and “truth” both inside and outside the lens.

Exhibition View, 2024

In another visual piece, “The Hairy Space Odyssey,” the artist uses her own hair as a metaphorical medium to narrate her growth story through a voice-over. The title “Odyssey” is drawn from Homer’s “Epic Odyssey,” representing the journey of an adventurer. Through Barbie dolls, the artist constructs a parallel universe covertly delving into topics related to hair and feminism. Such is the nature of Si Tong’s work, which not only conveys a refined calmness of the object but also captivates the audience with the expressions of the self and trauma, time, space, and growth. As she describes, although most of her works come from personal experiences in daily life, like an alchemist, the artist transcends the individual ego in her works, turning towards a collective human memory – the so-called “personal is political.” By combining her experiential system with modern imaging techniques, the artist has created a clandestine thread where feelings, perceptions, and visions gradually intensify to achieve an emotional resonance between the object and the environment itself.

Media Contact
Company Name: BluBlu LLC
Contact Person: Hanx
Email: Send Email
Country: United States
Website: www.blublu.space

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In the Midst of Danger: Sitong Cao Solo Exhibition

Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon

DelveInsight’s “Glaucoma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Glaucoma Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Glaucoma Market Forecast. Click here to stay ahead in healthcare innovation @ Glaucoma Market Size

Key Takeaways from the Glaucoma Market Report

The Glaucoma diagnosed prevalent cases were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.
Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight’s estimates, of all POAG cases in the 7MM, 52% were of NTG type.
Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.
The leading Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
Promising Glaucoma Pipeline Therapies such as NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.

Navigate the complexities of the Glaucoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Glaucoma Market Forecast. Click here to get more insights @ Glaucoma Treatment Market

Glaucoma Epidemiology Segmentation in the 7MM

Total Glaucoma Prevalence Cases
Prevalent Cases of Glaucoma by severity
Glaucoma Gender-specific Prevalence Cases
Diagnosed Cases of Episodic and Chronic Glaucoma

Delve deep into the Glaucoma Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Glaucoma Market Forecast. Click here to shape the future @ Glaucoma Prevalence

Glaucoma Market Insights

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But, treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination.

Glaucoma Treatment Market Landscape

Management of the condition revolves around reducing intraocular pressure (IOP) through the use of current drug classes, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. Despite these treatments, some patients do not experience the desired improvement in their condition. They may still face optic nerve damage even when their IOP levels are within the normal range. In addition to pharmacological treatments, alternatives such as incisional surgery, laser surgery, and medications are also considered.

Glaucoma Drugs Uptake

NCX 470 is a novel NO-donating bimatoprost eye drop, which is a prostaglandin analog. The drug is currently being developed by Nicox Ophthalmics and is in Phase III of clinical development. It is being developed for the treatment of open-angle glaucoma or ocular hypertension in the US. NCX 470 is designed to release bimatoprost and NO following instillation into the eye.
PDP-716 is a novel, once-a-day formulation of brimonidine developed using SPARC’s TearAct technology for the treatment of glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine, one of the most commonly used treatments for glaucoma and ocular hypertension.
STN-1012600 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, STN-1012600 is expected to give new therapeutic options for treating glaucoma.

Glaucoma Market Outlook

The report’s outlook on the Glaucoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glaucoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glaucoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glaucoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Major Glaucoma Companies

Several Glaucoma Companies working in the market include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.

Unlock insights into the Glaucoma Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Glaucoma Market Forecast. Click here @ Glaucoma Market Drivers and Barriers

Scope of the Glaucoma Market Research Report

Coverage- 7MM
Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Gain a strategic edge in the Glaucoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Glaucoma Market Forecast. Click here to lead in advancements @ Glaucoma Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise Glaucoma Market Overview at a Glance

4. Glaucoma Market Overview by Class

5. Methodology of Glaucoma Epidemiology and Market

6. Executive Summary of Glaucoma

7. Key Events

8. Disease Background and Overview of Glaucoma

9. Epidemiology and Patient Population

10. Patient Journey

11. Glaucoma Marketed Therapies

12. Glaucoma Emerging Therapies

13. Glaucoma Market Analysis

14. Key Opinion Leaders’ Views

15. Glaucoma SWOT Analysis

16. Glaucoma Unmet needs

17. Glaucoma Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon

Postpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace

DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size

Key Takeaways from the Postpartum Depression Market Report

July 2024:- Reunion Neuroscience Inc.:- The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
July 2024:- Gerbera Therapeutics Inc.- A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression. The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
The total diagnosed prevalent population of Postpartum Depression in the 7 major markets was found to be 1,155,349 in 2020. In case of Postpartum Depression patients in the United States, the diagnosed prevalent cases were found to be 620,944 in 2020, which is expected to increase by 2032.
In the EU5 countries the diagnosed prevalence of Postpartum Depression was found to be maximum in France with 99,815 cases, followed by the United Kingdom with 99,520 cases in2020. While, the least number of cases were found in Spain, i.e., 57,396 in 2020.
The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
Promising Postpartum Depression Therapies such as Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.

Delve deep into the Postpartum Depression Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Postpartum Depression Market Forecast. Click here to shape the future @ Postpartum Depression Prevalence

Postpartum Depression Overview

Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.

Postpartum Depression Epidemiology Insights

Total Diagnosed Prevalent Population
Type-specific Diagnosed Prevalence

Navigate the complexities of the Postpartum Depression Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Postpartum Depression Market Forecast. Click here to get more insights @ Postpartum Depression Treatment Market

Postpartum Depression Market Insights

Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in the treatment of PPD. Other treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary. Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR(Fluvoxamine Maleate) and Paxil CR (paroxetine) form the mainstay drug treatment for PPD. Although these drugs are approved for treating depression related disorders such as major depressive disorder (MDD), obsessive compulsive disorder (OCD), post – traumatic stress disorder (PTSD),treatment-resistant depression (TRD), etc., but they are being used as off-label drugs for the Postpartum Depression treatment.

Postpartum Depression Drug Market

The majorly used current therapeutic classes for treating PPD include Selective serotonin reuptake inhibitors (SSRIs), Serotonin non-epinephrine reuptake inhibitors (SRNIs), Atypical anti-depressants and Anti-psychotics Combination therapies (SSRIs and SRNIs). Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Postpartum Depression. Owing to the positive outcomes of the few products during the developmental stage by key players such as Sage Therapeutics and others, the market is expected to witness a significant positive shift in the Postpartum Depression Market Size

Postpartum Depression Market Dynamics

The dynamics of Postpartum Depression (PPD) market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2024-2034.

Postpartum Depression Drugs Uptake

Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type A γ-aminobutyric acid (GABAA ) receptors and a pharmacokinetic profile that is intended for daily oral dosing. The drug is being study in NEST program for PPD, under this one phase III (ROBIN Study; NCT02978326; 30 mg dose) is completed and second study (SKYLARK study; NCT04442503; 50 mg dose) is recruiting. The results from Robin study had shown a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p = 0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up.
Brii Biosciences is developing BRII-296, a GABAA PAM, for treating PPD. The company started the phase I trial in April 2021 and expects to start phase III trial in H1 2022 and a trial for PPD prevention is under consideration. The topline data readout for Phase I study was expected in 4Q 2021.
Lipocine’s LPCN1154 Is an oral neuron-steroid being developed for the treatment of PPD. The drug is expected to be an “at home” treatment with easier treatment access than the current standard of care invasive option that requires hospitalization with significant limitations. Moreover, LPCN 1154 is expected to provide the required level of privacy for a mother, avoiding bonding/breast feeding interruptions due to the required hospitalizations for the current option. The company has completed a phase I PK study to assess dose proportionality with LPCN 1154 in which dose proportionality was observed and phase II trial is in progress, as per the company’s pipeline, as the US FDA had cleared the Investigational New Drug Application to initiate a Phase II study to evaluate the therapeutic potential of LPCN 1154 for the treatment of PPD in adults.

Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers

Scope of the Postpartum Depression Market Report

Coverage- 7MM
Study Period- 2020-2034
Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
Postpartum Depression Therapies- Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.
Postpartum Depression Market Dynamics: Postpartum Depression Market drivers and Postpartum Depression Market Barriers
Postpartum Depression Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement

Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

4 Executive Summary of Postpartum Depression

5 Key events

6 Disease Background and Overview

7 Treatment and Management

8 Methodology

9 Epidemiology and Patient Population

10 Patient Journey

11 Marketed Therapies

12 Emerging Therapies

13 Postpartum Depression (PPD): Seven Major Market Analysis

14 KOL Views

15 SWOT Analysis

16 Unmet Needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace

Artificial Intelligence in Healthcare Market is Booming, the Market is Set to Skyrocket to $153.61 Billion by 2029 – Arizton

“AI In Healthcare Market Research Report by Arizton”

More than $140 Billion Opportunities in the Next 6 Years.

According to Arizton’s latest research report, artificial intelligence in healthcare market is growing at a CAGR of 48.50% during 2023-2029.

Curious to Know More About the Market? Click: https://www.arizton.com/market-reports/healthcare-artificial-intelligence-market

Report Scope    

Market Size (2029): $153.61

Market Size (2023): $14.33 Billion   

CAGR (2023-2029): 48.50%  

Historic Year:  2020-2022   

Base Year: 2023   

Forecast Year: 2024-2029   

Market Segmentation: Component, Application, Technology, End-Users, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

Surge in AI Startups Revolutionizes Healthcare Industry

The rise of artificial intelligence (AI) in healthcare has spurred a significant increase in the number of new startups worldwide. These emerging companies are introducing innovative tools and technologies, transforming the healthcare landscape. Each year, the number of new AI healthcare startups has grown dramatically, from 12-15 annually in the past decade to over 70-110 in recent years. This surge is largely driven by the growing capability of these startups to offer remote treatment options, which is particularly beneficial in areas with limited medical facilities.

Investment in AI healthcare startups has also seen substantial growth. In 2021 alone, over $20 billion was invested in healthcare technologies, reflecting a sharp increase in funding compared to previous years. According to the AI Index Report 2023 by Stanford University, healthcare received the highest investment focus in 2022, with $6.1 billion invested globally. This is a significant rise from the $4 billion invested in 2019, which included over 350 deals.

The rising digitalization of healthcare, supportive government policies, and advancements in the field are creating ample opportunities for AI startups. Most of these new ventures are emerging from the US, Israel, India, and Europe. As a result, the growth of AI healthcare startups is set to continue, offering substantial market opportunities and advancements in healthcare delivery.

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here: https://www.arizton.com/subscription            

Pharma & Biotech Segment in AI Healthcare Market Poised for Exponential Growth

Pharma & Biotech and Medical Device Companies Witnessing the Fastest Growth Rate

In 2023, the pharma & biotech, and medical device companies segment in the AI healthcare market was valued at $3.08 billion.

AI’s transformative impact on the pharmaceutical and biotech sectors is evident in its application across various functions, particularly in improving data processing and research and development (R&D). Deep learning technology has found innovative applications in real-world clinical settings, enhancing production processes, quality control, drug design efficiency, predictive maintenance, and waste reduction.

The biotech industry has notably benefited from AI advancements, which have accelerated drug discovery and reduced costs. The COVID-19 pandemic further accelerated AI adoption, highlighting its value in diagnostics, treatment development, and vaccine creation. AI’s role in drug discovery has led to several breakthroughs, streamlining processes and increasing efficiency.

In 2023, significant investments in AI by leading pharmaceutical companies underscore its growing importance. Sanofi is leveraging AI for mRNA research, AstraZeneca has invested approximately $840 million, and Boehringer Ingelheim partnered with Phemonic AI, committing $500 million. Pfizer is utilizing Google Cloud for its AI initiatives, while Novartis is focusing on generative AI and integrating AI into around 150 global clinical trials. These investments highlight AI’s critical role in advancing the pharma and biotech industries.

Recent Vendors Activities in the Global AI in Healthcare Market

In 2024, Google Cloud launched a tool by generative AI that allows clinicians to search information across patient notes, clinical data, and scanned documents- Vertex AI. Furthermore, in 2023, Google introduced MedLM, a generative AI model for healthcare with two generative AI tools based on the language model Med-PaLM 2.
In 2024, NVIDIA Healthcare launched new generative AI microservices for chemistry, biology, imaging, and healthcare information in each NVIDIA DGX Cloud.
In 2024, Epic – a HER giant company, plans to launch new AI validation software for healthcare settings to test and monitor several procedures.
In 2024, Salesforce launched an AI solution for health workers, which helps automate some administrative tasks that minimize physician burnout.

In 2023, Microsoft launched a series of Health AI initiatives, including a partnership announcement with EPIC, and launched DAX ambient clinical noting with its Nuance subsidiary.
In 2023, LeanTaas launched the iQueue Autopilot generative AI tool for hospital operators. This tool allows human-like conversation and actionable insight into patients and staffing.

Buy this Research @ https://www.arizton.com/market-reports/healthcare-artificial-intelligence-market

Key Vendors

Google Health
Intel Corporation
Medtronic
Microsoft
NVIDIA Corporation
Siemens Healthineers
Amazon Web Services
Merative
Augmedix
CloudMedx Health
BioSymetrics
Corti
Butterfly Network, Inc.
Enlitic
TEMPUS
Behold.ai
oxipit.ai
Clarius
General Vision
Koninklijke Philips N.V.
Stryker
Shimadzu Recursion Pharmaceuticals
GE Healthcare
Subtle Medical
Sensely
InformAI
Clario
Owkin
Binah.AI
Oncora Medical
Qure.ai
Lunit
Caresyntax
Anju Software
DEEP GENOMICS
MDLIVE
Qventus
WorkFusion
Salesforce
LeenTaaS

Segmentation & Forecast

Component

Software & Services
Hardware

Application

Hospital Workflow Management
Patient Management
Medical Imaging and Diagnosis
Drug Discovery and Precision Medicine

Technology

Machine Learning
Deep Learning
Natural Language Processing
Vision AI
Other Technologies

End-user

Healthcare Providers
Pharma & Biotech and Medical Device Companies
Payers
Other End-users

Key Questions Answered in the Report:   

How big is the global AI in healthcare market?

Which region dominates the global AI in healthcare market?

What is the growth rate of global AI in healthcare market?

What are the opportunities in the global AI in healthcare market?

Who are the major players in the global AI in healthcare market?

Check Out Some of the Top Selling Research Reports:   

Global Artificial Intelligence (AI) In Genomics Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/artificial-intelligence-in-genomics-market

Global AI in Medical Imaging Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/artificial-intelligence-in-medical-imaging-market

Why Arizton?                                   

100% Customer Satisfaction                                   

24×7 availability – we are always there when you need us                                   

200+ Fortune 500 Companies trust Arizton’s report                                   

80% of our reports are exclusive and first in the industry                                   

100% more data and analysis                                   

1500+ reports published till date                 

Post-Purchase Benefit                               

1hr of free analyst discussion                               
10% off on customization

About Us:                                                                        

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                      

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                       

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                                   

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707            
Country: United States
Website: https://www.arizton.com/market-reports/healthcare-artificial-intelligence-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Artificial Intelligence in Healthcare Market is Booming, the Market is Set to Skyrocket to $153.61 Billion by 2029 – Arizton

The US Air Purifier Market to Hit $5.04 Billion by 2029, HEPA Purifier to Capture the Major Market Share – Arizton

“U.S. Air Purifier Market Research Report by Arizton”

Market to Witness Shipments of More than 8.9 Million Units Sales (2029).

According to Arizton’s latest research report, the US air purifier market is growing at a CAGR of 10.88% during 2023-2029.

Curious to Know More About the Market? Click: https://www.arizton.com/market-reports/us-air-purifier-market

Report Scope    

Market Size (2029): $5.04 Billion   

Market Size (2023): $2.71 Billion   

CAGR (2023-2029): 10.88%  

Market Size – Volume (2029): 8.91 Million Units   

Historic Year:  2020-2022   

Base Year: 2023   

Forecast Year: 2024-2029   

Market Segmentation: Technology, CADR, Distribution Channel, and Application

The air purifier market has witnessed a significant shift with the introduction of smart, connected air purifiers. These innovative devices allow seamless operation and air quality monitoring via dedicated mobile applications. This development enhances user convenience and reflects the growing demand for interconnected home devices that offer personalized solutions. Market players should embrace this trend by investing in smart technology integration and user-friendly interfaces to stay relevant and meet the evolving needs of consumers.

Major US air purifier market players include Honeywell, Blueair, and Dyson. These companies are recognized for innovation, high product quality, and strong brand presence. They invest heavily in research and development to introduce new technologies and enhance existing products, focusing on improvements such as filtration efficiency, noise reduction, and smart connectivity. Their efforts to expand product offerings and incorporate advanced features help them maintain a competitive edge and attract a broad range of consumers.

The market serves various consumer segments with distinct needs. Individuals with respiratory conditions like asthma and allergies seek air purifiers that effectively reduce airborne triggers. General households prioritize maintaining a healthy living environment, while commercial establishments—such as offices, hotels, and retail stores—use air purifiers to boost customer and employee health and satisfaction.

Economic factors significantly influence the US air purifier market. Economic stability and higher disposable income allow consumers to invest in premium air purifiers with advanced features. Conversely, economic downturns or fluctuations may increase demand for more affordable options. Manufacturers must adapt to these economic conditions by offering a diverse product range to cater to both high-end and budget-conscious consumers.

New Product Innovations

April 2023 marked a milestone in the air purifier market as Xiaomi unveiled its latest innovation, the Xiaomi Smart Air Purifier 4. Boasting a particle clean air delivery rate (PCADR) of up to 400m³/h and an impressive output of 6660L of purified air per minute, this cutting-edge device features 360° all-round air intake. With its advanced technology and efficient performance, the Xiaomi Smart Air Purifier 4 is poised to set new standards in air purification, providing consumers with cleaner and healthier indoor environments. Market players should take note of this development and strive to enhance their product offerings to remain competitive in an evolving landscape.

March 22, 2024, witnessed the spotlight shining on 3M for its innovative Filtrete Smart Room air purifiers. Designed to cater to various room sizes, including medium rooms with the FAP SC02W model and large rooms with the FAP ST02 model, these smart air purifiers exemplify technological innovation driving market growth. By leveraging smart features and tailored solutions, 3M is poised to capture consumer interest and drive market expansion. Competitors should take note of this trend and invest in similar technological advancements to meet evolving consumer demands and stay ahead in the competitive landscape.

HEPA Purifier Leading the Market

HEPA filters are highly valued for their effectiveness in removing particulate matter, allergens, and pollutants from the air, making them a popular choice for those seeking efficient air purification. They are extensively used in hospitals to maintain sterile environments and in homes to alleviate allergens like pollen and pet dander. Leading brands such as Dyson and Blueair leverage HEPA technology to offer high-quality air purifiers consumers worldwide trust.

In the US, HEPA air purifiers are prevalent, especially in urban areas with significant air quality issues due to pollution and dense populations. HEPA filters’ proven reliability and performance have fostered consumer trust, sustaining demand across residential, commercial, and industrial settings where clean air is crucial.

The adoption of HEPA filters is also supported by stringent air quality regulations, such as the Clean Air Act (CAA), which governs emissions to protect public health and the environment. This regulatory framework enhances the uptake of HEPA filters, particularly in regions with strict environmental standards.

Overall, the HEPA filter segment is experiencing strong growth, driven by increased awareness of health risks associated with poor air quality and the expanding use of air purifiers in various settings.

Buy this Research @ https://www.arizton.com/market-reports/us-air-purifier-market

Key Vendors

Blue Star

Daikin Applied

Dyson

Honeywell

Midea Group

Panasonic Corporation

Philips

Sharp

Whirlpool

Aldes

Alen

AllerAir

AustinAir

Beyond

Bionaire

Blueair

Boneco

Coway

ENVION

Hamilton Beach Brands

Holmes

Homedics

IQAir

Lasko

Lennox

Levoit

LG Electronics

Molekule

Oransi

Pro Breeze

Pure Enrichment

Rabbit Air

Robert Bosch

TruSens

WYND Technologies

Xiaomi

Segmentation & Forecast

Technology

HEPA

Ionic

Activated Carbon

Photocatalytic

Electrostatic Precipitators

Others

CADR

Medium

High

Distribution Channel

Offline

Online

Application

Residential

Office Spaces

Hospitals

Hospitality

Educational Institutes

Airports

Shopping Malls

Gyms and Fitness Centers

Government Centers

Others

Key Questions Answered in the Report:   

How big is the U.S. air purifier market?

What is the growth rate of the U.S. air purifier market?

What are the key trends in the U.S. air purifier market?

What is the expected number of air purifier shipments in the U.S. market by 2029?

Who are the major players in the U.S. air purifier market?

Check Out Some of the Top Selling Research Reports:   

Air Shower Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/air-shower-market

Water Heater Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/water-heater-market

Why Arizton?                                   

100% Customer Satisfaction                                   

24×7 availability – we are always there when you need us                                   

200+ Fortune 500 Companies trust Arizton’s report                                   

80% of our reports are exclusive and first in the industry                                   

100% more data and analysis                                   

1500+ reports published till date                 

Post-Purchase Benefit                               

1hr of free analyst discussion

10% off on customization

About Us:                                                                        

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707  
Country: United States
Website: https://www.arizton.com/market-reports/us-air-purifier-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The US Air Purifier Market to Hit $5.04 Billion by 2029, HEPA Purifier to Capture the Major Market Share – Arizton

Building Information Modeling Market worth $14.8 Billion by 2029, at a CAGR of 13.1%

“Building Information Modeling Market”

The global Building Information Modeling Market in terms of revenue was estimated to be worth $8.0 billion in 2024 and is poised to reach $14.8 billion by 2029, growing at a CAGR of 13.1% during the forecast period.

The report “Building Information Modeling Market by Offering (Software, Services), Deployment Type (On-Premises), Project lifecycle (Pre construction), End User (AEC Professionals), Application (Planning & Modelling) and Region – Global Forecast to 2029” The Building Information Modeling Market is projected to reach from USD 8.0 billion in 2024 to USD 14.8 billion by 2029; it is expected to grow at a CAGR of 13.1% from 2024 to 2029. The increasing demand for BIM solutions is attributed to advanced sustainability with BIM and rapid rise in urbanization globally.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95037387

Browse 150 market data Tables and 70 Figures spread through 250 Pages and in-depth TOC on “Building Information Modeling Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/building-information-modeling-market-95037387.html

By Offering Type: Service segment is projected to grow at the highest CAGR during the forecast period.

BIM as a Service (BIMaaS) allows for real-time access to BIM models and data via internet connectivity, facilitating enhanced collaboration among project teams, stakeholders, and partners irrespective of their geographic locations. This accessibility fosters seamless communication and decision-making across distributed teams. Moreover, BIMaaS providers offer customizable services tailored to meet specific project needs, including capabilities such as 3D modeling, clash detection, scheduling, cost estimation, and facility management. This flexibility empowers organizations to choose and pay for precisely the services required, optimizing resource allocation and budget management effectively.

By Project lifecycle: Preconstruction to account for the highest CAGR during the forecast period.

The pre-construction segment holds the largest market share in the building information modeling (BIM) market. Utilizing BIM during the pre-construction phase can increase construction speed and lower costs, as well as decrease on-site rework and material waste, contributing to environmental sustainability. By identifying and addressing clashes and issues before construction starts, BIM helps ensure a smoother and more efficient construction process.

By Deployment Type: The cloud-based BIM solutions is projected to register the highest CAGR during the forecast period.

Cloud-based BIM solutions integrate effortlessly with other cloud-based tools and services, such as project management software, data analytics platforms, and IoT devices. This integration boosts the overall functionality and efficiency of BIM workflows. Additionally, cloud service providers manage software updates, maintenance, and security patches, ensuring users always have access to the latest features and improvements without requiring manual intervention.

By Region: North America to hold larger market share in 2023.

North America holds a significant share in the building information modeling (BIM) industry, with the market encompassing the US, Canada, and Mexico. Leading companies driving this market include Autodesk Inc., Bentley Systems, Trimble Inc., Procore Technologies, Inc. The US is expected to lead the BIM market in North America. It hosts several tier 1 companies and is at the forefront of adopting advanced digital systems within the infrastructure sector. This leadership position underscores the region’s robust adoption of BIM technologies across various construction and engineering projects.

Key Players

The building information modeling companies include Autodesk Inc. (US), Nemetschek Group (Germany), Bentley Systems, Incorporated (US), Trimble Inc. (US), Dassault Systèmes (France).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/building-information-modeling-market-95037387.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Building Information Modeling Market worth $14.8 Billion by 2029, at a CAGR of 13.1%

Hepatitis B Virus Infection Pipeline Drugs 2024 | FDA Approvals, Clinical Trials, and Companies

DelveInsight, “Hepatitis B Virus Infection Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatitis B Virus Infection Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hepatitis B Virus Infection Pipeline Outlook

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

July 2024:- GlaxoSmithKline- A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment. This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with Human Immunodeficiency Virus (HIV)/Hepatitis B Virus (HBV) co-infection.
July 2024:- Gilead Sciences- A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
The leading Hepatitis B Virus Infection Companies such as Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
Promising Hepatitis B Virus Infection therapies such as BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

Stay ahead with the most recent pipeline outlook for Hepatitis B Virus Infection. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatitis B Virus Infection Treatment Drugs

Hepatitis B Virus Infection Emerging Drugs

Bepirovirsen: GSK

Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognise the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) which facilitate chronicity of the disease by helping to avoid clearance by the immune system. The ASO recruits the liver’s own enzymes to eliminate the RNA by digesting it to an inactive form. The subsequent reduction in the levels of the RNA results in a decrease in both the virus and the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the HBV DNA and antigen levels in the circulating blood. Bepirovirsen has an additional property of stimulating immune responses via Toll-like receptor 8 (TLR8) which may help the immune system to achieve durable clearance of the virus from circulating blood.

VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. Currently, the drug is in the Phase II stage of its development for the treatment of Hepatitis B Virus Infection.

AB 729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase IIa randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.

AHB-137: Ausper Biopharma

AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential to be a backbone for the functional cure of CHB. In June 2023, AusperBio announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure. AHB-137’s highly potent antiviral activity in preclinical studies, along with its favorable pharmacokinetics and safety profile, garnered significant attention and recognition. Currently, the drug is in the Phase I stage of its development for the treatment of Hepatitis B Virus Infection.

Explore groundbreaking therapies and clinical trials in the Hepatitis B Virus Infection Pipeline. Access DelveInsight’s detailed report now! @ New Hepatitis B Virus Infection Drugs

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatitis B Virus Infection Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Hepatitis B Virus Infection Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatitis B Virus Infection Market Drivers and Barriers

Scope of the Hepatitis B Virus Infection Pipeline Report

Coverage- Global
Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
Hepatitis B Virus Infection therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.
Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hepatitis B Virus Infection Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hepatitis B Virus Infection Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Hepatitis B Virus Infection: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Bepirovirsen: GSK
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
VIR 2218: Vir Biotechnology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AHB-137: Ausper Biopharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hepatitis B Virus Infection Key Companies
Hepatitis B Virus Infection Key Products
Hepatitis B Virus Infection- Unmet Needs
Hepatitis B Virus Infection- Market Drivers and Barriers
Hepatitis B Virus Infection- Future Perspectives and Conclusion
Hepatitis B Virus Infection Analyst Views
Hepatitis B Virus Infection Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus Infection Pipeline Drugs 2024 | FDA Approvals, Clinical Trials, and Companies